Search results for "Convulsants"

showing 10 items of 125 documents

Short-Term Neurodevelopmental Outcome in Term Neonates Treated with Phenobarbital versus Levetiracetam: A Single-Center Experience

2019

Background. Phenobarbital (PB) has been traditionally used as the first-line treatment for neonatal seizures. More recently, levetiracetam (LEV) has been increasingly used as a promising newer antiepileptic medication for treatment of seizures in neonates. Objectives. The aim of our study was to compare the effect of PB vs. LEV on short-term neurodevelopmental outcome in infants treated for neonatal seizures. Method. This randomized, one-blind prospective study was conducted on term neonates admitted to the Neonatal Intensive Care Unit of S. Bambino Hospital, University Hospital “Policlinico-Vittorio Emanuele,” Catania, Italy, from February 2016 to February 2018. Thirty term neonates with s…

MalePediatricsmedicine.medical_specialtyNeonatal intensive care unitLevetiracetamArticle Subjectneonatal seizures levetiracetam neurodevelopmental outcomemedicine.medical_treatmentneonatal seizuresNeurological examinationNeurosciences. Biological psychiatry. NeuropsychiatrySingle CenterNO03 medical and health sciences0302 clinical medicineSeizures030225 pediatricsmedicineHumansProspective StudiesProspective cohort studymedicine.diagnostic_testbusiness.industryInfant NewbornAnticonvulsants Treatment Outcome Infant Newborn Italy Levetiracetam Neurodevelopmental Disorders Phenobarbital SeizuresInfantPhenobarbital; neonatal seizures; LevetiracetamGeneral MedicineTerm neonatesNewbornNeuropsychology and Physiological PsychologyAnticonvulsantTreatment OutcomeNeurologyItalyNeurodevelopmental DisordersPhenobarbitalClinical StudyPhenobarbitalFemaleAnticonvulsantsNeurology (clinical)Levetiracetambusiness030217 neurology & neurosurgerymedicine.drugRC321-571Behavioural Neurology
researchProduct

Cognitive-behavioral screening in elderly patients with new-onset epilepsy before treatment

2014

Objectives Cognitive comorbidity at epilepsy onset reflects disease severity and provides a baseline estimate of reserve capacities with regard to the effects of epilepsy and its treatment. Given the high incidence of epilepsy at an older age, this study analyzed objective and subjective cognition as well as quality of life in elderly patients with new-onset focal epilepsy before initiation of anti-epileptic treatment. Materials and methods A total of 257 untreated patients (60–95 years of age) with new-onset epilepsy underwent objective assessment of executive function (EpiTrack) and performed subjective ratings of cognition (Portland Neurotoxicity Scale) and quality of life (QoL; QOLIE-31…

MalePediatricsmedicine.medical_specialtymedia_common.quotation_subjectComorbidityExecutive FunctionEpilepsyDouble-Blind MethodmedicineHumansAgedmedia_commonAged 80 and overEpilepsyIncidenceNeuropsychologyCognitionGeneral MedicineMiddle AgedExecutive functionsmedicine.diseaseComorbidityNeurologyQuality of LifeEtiologyPhysical therapyAnticonvulsantsFemaleNeurology (clinical)Cognition DisordersPsychologyBody mass indexVigilance (psychology)Acta Neurologica Scandinavica
researchProduct

Phenytoin-induced glutathione depletion in rat peripheral nerve

1995

Abstract Administration of high doses (150–250 mg/kg body weight) of phenytoin (DPH) promote a 40% decrease in glutathione (GSH) content of rat sciatic nerve. This DPH-induced GSH depletion is accompanied with an electrophysiological impairment of peripheral neuromuscular function. H7 (20 mg/kg body weight IP, 30 min prior to DPH), a protein kinase C inhibitor, was able to prevent the DPH-induced GSH depletion only at the lower DPH dose used. This same inhibitor completely prevented the electrophysiological impairment at the lower DPH dose, and only partially at the higher DPH dose used. These results confirm the hypothesis of a DPH-dependent activation of PKC (that might be triggered by, o…

MalePhenytoinAntioxidantmedicine.medical_treatmentAction PotentialsIn Vitro TechniquesPharmacologymedicine.disease_causeBiochemistryPiperazineschemistry.chemical_compound1-(5-Isoquinolinesulfonyl)-2-MethylpiperazinePhysiology (medical)polycyclic compoundsmedicineAnimalsEnzyme InhibitorsRats WistarMuscle SkeletalEvoked PotentialsProtein Kinase CProtein kinase CMotor NeuronsAnalysis of Variancetechnology industry and agricultureNeurotoxicityGlutathioneIsoquinolinesmedicine.diseaseGlutathioneSciatic NerveRatsKineticschemistryBiochemistryPhenytoinAnticonvulsantslipids (amino acids peptides and proteins)Sciatic nerveOxidative stressIntracellularmedicine.drugFree Radical Biology and Medicine
researchProduct

Novel Potent Anticonvulsant Agent Containing a Tetrahydroisoquinoline Skeleton

2006

In our studies on the development of new anticonvulsants, we planned the synthesis of N-substituted 1,2,3,4-tetrahydroisoquinolines to explore the structure-activity relationships. All derivatives were evaluated against audiogenic seizures in DBA/2 mice, and the 1-(4'-bromophenyl)-6,7-dimethoxy-2-(piperidin-1-ylacetyl) derivative (26) showed the highest activity with a potency comparable to that of talampanel, the only noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonist in clinical trials as an anticonvulsant agent. Electrophysiological experiments indicated that 26 acts as noncompetitive AMPA receptor modulator.

MaleStereochemistrymedicine.medical_treatmentAMPA receptorIn Vitro TechniquesChemical synthesisMiceStructure-Activity Relationshipchemistry.chemical_compoundPiperidinesSeizuresTetrahydroisoquinolinesAMPADrug DiscoverymedicineAnimalsPotencyReceptors AMPARats WistarTalampanelTetrahydroisoquinolineAntagonistAMPA; Isoquinolines; anticonvulsantsOlfactory PathwaysIsoquinolinesRatsAnticonvulsant AgentAnticonvulsantAcoustic StimulationchemistryMice Inbred DBAMolecular MedicineAnticonvulsants
researchProduct

Non-convulsive status epilepticus associated with tiagabine in a pediatric patient

2003

We report a 4-year-old patient who developed non-convulsive status epilepticus (NCSE) following tiagabine (TGB) as add-on treatment for refractory partial seizures. NCSE occurred while the patient received TGB 0.83mg/kg/day. In our case, the TGB reduction led to a significant improvement of electroclinical features. The mechanisms of this abnormal effect are not clear. GABA-ergic hyperfunction and/or multiplicity of interlinked brain GABA systems associated with individual specific sensitivity could play a critical role in the pathogenesis of NCSE. This is the first report of NCSE documented by electroencephalogram (EEG) in a child under 12 years of age on TGB treatment. © 2003 Elsevier Sci…

MaleTiagabinemedicine.medical_treatmentNipecotic AcidsStatus epilepticusNon-convulsive status epilepticuElectroencephalographyCentral nervous system diseaseEpilepsyStatus EpilepticusDevelopmental NeuroscienceRefractorymedicineHumansTiagabineEpilepsymedicine.diagnostic_testbusiness.industryElectroencephalographyGeneral Medicinemedicine.diseaseAnticonvulsantnervous systemEl NiñoChild PreschoolAnesthesiaPediatrics Perinatology and Child HealthAnticonvulsantsEpilepsies PartialNeurology (clinical)medicine.symptombusinessmedicine.drugBrain and Development
researchProduct

Continuous intra-amygdalar infusion of GABA in the amygdala kindling model of epilepsy in rat.

2003

Objective: To explore the effect of continuous intra-amygdalar infusion of GABA in the amygdala kindling model of epilepsy in rat. Methods: An electrode and cannula complex was implanted in adult male Wistar rats, the electrode being targeted to the left basolateral amygdala. The animals were subjected to a standard kindling procedure. Osmotic minipumps filled with either GABA or mannitol were connected to cannulas and allowed to infuse during 7 days. Kindling experiments measuring after-discharge and seizure thresholds, seizure severity and duration, and behavioral toxicity were performed before, during and after the drug infusion period. Results: Both after-discharge and seizure threshold…

MaleTime FactorsCentral nervous systemPharmacologyAmygdalachemistry.chemical_compoundEpilepsyBasal gangliamedicineKindling NeurologicAnimalsRats WistarNeurotransmittergamma-Aminobutyric AcidEpilepsyDose-Response Relationship Drugbusiness.industryKindlingInfusion Pumps Implantablemedicine.diseaseAmygdalaElectric StimulationRatsDisease Models Animalmedicine.anatomical_structurenervous systemNeurologychemistryAnesthesiaToxicityAnticonvulsantsNeurology (clinical)businessBasolateral amygdalaEpilepsy research
researchProduct

Antiepileptic effect of dimethyl sulfoxide in a rat model of temporal lobe epilepsy.

2012

Dimethyl sulfoxide (DMSO) is an amphipathic molecule widely used to solubilize water-insoluble compounds. In many studies it was reported that DMSO is capable of affecting several biological processes, thus resulting in a potential cause for the misinterpretation of experimental data. Recent papers showed that DMSO modified the brain bioelectric activity in animal models of epilepsy. In an in vivo model of temporal lobe epilepsy in the rat, we examined the effects of different doses (10%, 50% and 100%) of DMSO on the maximal dentate activation (MDA). The results show that DMSO induced a dose-dependent significant reduction of the electrically induced paroxysmal activity.

MaleTreatment outcomeRat modelAction PotentialsPharmacologySettore BIO/09 - FisiologiaTemporal lobeEpilepsychemistry.chemical_compoundIn vivomedicineAnimalsHumansDimethyl SulfoxideRats WistarTemporal lobe epilepsyDose-Response Relationship DrugChemistryDimethyl sulfoxideGeneral Neurosciencemedicine.diseaseRatsDose–response relationshipDisease Models AnimalMaximal dentate activationTreatment OutcomeBiochemistryCerebellar NucleiEpilepsy Temporal LobeSolubilizationAnticonvulsantsNeuroscience letters
researchProduct

Inhibitory effects of N-valproyl-L-tryptophan on high potassium, low calcium and low magnesium-induced CA1 hippocampal epileptiform bursting activity…

2012

N-valproyl-l-tryptophan (VPA-Tryp), new antiepileptic drug, was tested on CA1 hippocampal epileptiform bursting activity obtained by increasing potassium and lowering calcium and magnesium concentrations in the fluid perfusing rat brain slices. Each slice was treated with a single concentration (0.2, 0.5, 1 or 2 mM) of Valproate (VPA) or VPA-Tryp. Both burst duration and interburst frequency during and after treatment were off-line compared with baseline values. For both parameters, the latency and the length of statistically significant response periods as well as the magnitude of drug-induced responses were calculated. VPA-Tryp evoked fewer and weaker early excitatory effects than VPA on …

Maleantiepileptic drug valproic acidPotassiumchemistry.chemical_elementAction PotentialsCalciumHippocampal formationPharmacologyIn Vitro TechniquesInhibitory postsynaptic potentialSettore BIO/09 - Fisiologiaamino-acidic derivativeBurstingmedicineReaction Timehippocampal epilepsyAnimalsDrug InteractionsMagnesiumRats WistarCA1 Region HippocampalBiological PsychiatryValproic AcidAnalysis of VarianceDose-Response Relationship DrugMagnesiumDipeptidesElectric StimulationRatsPsychiatry and Mental healthNeurologychemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoExcitatory postsynaptic potentialPotassiuminterictal burstslipids (amino acids peptides and proteins)AnticonvulsantsNeurology (clinical)medicine.drugJournal of neural transmission (Vienna, Austria : 1996)
researchProduct

Impact of comorbidities on pharmacotherapy of painful diabetic neuropathy in clinical practice.

2014

Abstract Aims We evaluated the impact of baseline comorbidities on the effectiveness of duloxetine and anticonvulsants (pregabalin/gabapentin) in patients with painful diabetic neuropathy in clinical care. Methods Outcomes from a 6-month, observational study with 2575 patients initiating/switching DPNP treatment were analyzed post-hoc. Propensity scoring was used to adjust for baseline factors influencing treatment choice in 1523 patients receiving duloxetine or anticonvulsants. Analysis of covariance models with fixed effects for baseline pain, treatment, propensity score, baseline characteristics or comorbidities, and their interaction with treatment were used to estimate LSmean effects o…

Malemedicine.medical_specialtyGabapentinCyclohexanecarboxylic AcidsEndocrinology Diabetes and MetabolismPregabalinPregabalinComorbidityThiophenesDuloxetine Hydrochloridechemistry.chemical_compoundEndocrinologyDiabetic NeuropathiesInternal MedicinemedicineDuloxetineHumansPain ManagementBrief Pain InventoryAminesDepression (differential diagnoses)gamma-Aminobutyric AcidAgedPain MeasurementRetrospective StudiesAnalgesicsbusiness.industryChronic painMiddle Agedmedicine.diseasePrognosisTreatment OutcomechemistryJoint painPropensity score matchingPhysical therapyAnticonvulsantsFemalemedicine.symptomGabapentinbusinessmedicine.drugJournal of diabetes and its complications
researchProduct

Different forms of trigeminal autonomic cephalalgias in the same patient: description of a case.

2010

The trigeminal autonomic cephalalgias (TACs), including cluster headache, paroxysmal hemicrania and SUNCT, are characterized by the cardinal combination of short-lasting unilateral pain and autonomic phenomena affecting the head. Hemicrania continua (HC) shares many clinical characteristics with TACs, including unilateral pain and ipsilateral autonomic features. Nevertheless, HC is separately classified in the revised International Classification of Headache Disorders (ICHD-II). Here, we describe the case of a 45-year-old man presenting an unusual concurrence of different forms of primary headaches associated with autonomic signs, including subsequently ipsilateral cluster headache, SUNCT a…

Malemedicine.medical_specialtyHemicrania continua Cluster headache SUNCTTACsNeurologyCluster headacheClinical NeurologyCase ReportAutonomic Nervous SystemDiagnosis DifferentialSUNCTmedicineHumansParoxysmal HemicraniaTrigeminal NerveTrigeminal nerveSUNCT Syndromebusiness.industryCluster headacheAnti-Inflammatory Agents Non-SteroidalHeadacheHemicrania continuaGeneral MedicineCerebral ArteriesMiddle Agedmedicine.diseaseDermatologyTrigeminal Autonomic CephalalgiasAutonomic nervous systemAnesthesiology and Pain MedicineTreatment OutcomeHemicrania continuaAnesthesiaInternational Classification of Headache DisordersAnticonvulsantsSettore MED/26 - NeurologiaNeurology (clinical)Trigeminal autonomic cephalalgiabusinessTACs
researchProduct